凯时治疗糖尿病肾病的临床观察

Study on Lipopge1 in Treatment of Diabetic Nephropathy

目的观察凯时(lipoPGE1)治疗糖尿病肾病(DN)的临床疗效,并探讨其肾脏保护作用的机制。方法选择本院住院的2型糖尿病肾病120例,随机分为治疗组60例及对照组60例。两组均在糖尿病常规治疗(包括严格控制饮食、适量运动,口服降糖药或胰岛素治疗)的同时进行试验。治疗组加用凯时注射液治疗,疗程28d。观察两组治疗前后及组间24h尿白蛋白总量、血尿素氮和肌酐等相关指标的变化,并观察有无副作用。结果治疗组尿微量白蛋白及24h尿白蛋白总量、血尿素氮、肌酐降低,肾功能明显改善,与治疗前及对照组比较有显著性差异(P<0.05)。结论凯时明显改善糖尿病肾病的尿微量白蛋白、24h尿白蛋白总量及肾功能等指标,是一种治疗糖尿病肾病安全、有效的药物。

Objective To observe the effectiveness of lipoPGE1 in treatment of diabetic nephropathy and the mechanism of the renal protection of the drug.Methods One hundred and twenty patients with diabetic nephropathy due to type 2 diabetes mellitus were randomly divided into 2 groups, 60 in Treatment Group, and 60 as controls. LipoPGE1 was used intravenously in the Treatment Group for 4 weeks while routine management of diabetes such as food intake control, physical exercises and oral drugs or injection of insulin was conducted in both of the 2 grotrps. Urinary albumin of 24 hours, serum urea nitrogen and creatinine were employed for evaluation as well as the side-effects.Results By the end of the trial, urinary albumin, urinary albumin of 24 hours, serum urea nitrogen and creatinine were decreased significantly compared with those before intravenous lipoPGE1 treatment or with those in the controlled group （P〈0.05）. Conclusion Urinary albumin and urinary albumin of 24 hours were decreased significantly after intravenous lipoPEG1 treatment. Therefore, it is a safe and effective drug in the treatment of diabetic nephronathy .